2021 Form 10-K Financial Statement
#000161521922000028 Filed on March 25, 2022
Income Statement
Concept | 2021 | 2020 Q4 | 2020 |
---|---|---|---|
Revenue | $1.840M | $1.480M | $5.233M |
YoY Change | -64.84% | 42.31% | 51.03% |
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $6.105M | $1.210M | $6.110M |
YoY Change | -0.09% | -31.25% | -20.75% |
% of Gross Profit | |||
Research & Development | $8.549M | $2.020M | $6.914M |
YoY Change | 23.64% | 50.75% | 72.03% |
% of Gross Profit | |||
Depreciation & Amortization | $19.18K | $10.00K | $18.06K |
YoY Change | 6.23% | 0.0% | -85.83% |
% of Gross Profit | |||
Operating Expenses | $14.65M | $3.240M | $13.02M |
YoY Change | 12.55% | 4.52% | 10.99% |
Operating Profit | -$12.81M | -$7.786M | |
YoY Change | 64.56% | -5.79% | |
Interest Expense | $44.69K | -$10.00K | -$3.047K |
YoY Change | -1566.69% | -105.56% | -119.47% |
% of Operating Profit | |||
Other Income/Expense, Net | $0.00 | $0.00 | $180.0K |
YoY Change | -100.0% | 800.0% | |
Pretax Income | -$12.77M | -$1.770M | -$7.350M |
YoY Change | 73.72% | -5.85% | 5.91% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$12.77M | -$1.770M | -$7.352M |
YoY Change | 73.66% | -5.85% | 6.0% |
Net Earnings / Revenue | -693.84% | -119.59% | -140.49% |
Basic Earnings Per Share | -$0.31 | -$0.50 | |
Diluted Earnings Per Share | -$0.31 | -$113.6K | -$0.50 |
COMMON SHARES | |||
Basic Shares Outstanding | 41.37M shares | 19.84M shares | 15.58M shares |
Diluted Shares Outstanding | 41.37M shares | 15.58M shares |
Balance Sheet
Concept | 2021 | 2020 Q4 | 2020 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $29.21M | $11.10M | $11.12M |
YoY Change | 162.72% | 200.0% | 197.33% |
Cash & Equivalents | $29.21M | $11.12M | $11.12M |
Short-Term Investments | |||
Other Short-Term Assets | $949.2K | $137.8K | $820.0K |
YoY Change | 15.76% | 1.27% | -14.58% |
Inventory | |||
Prepaid Expenses | |||
Receivables | $0.00 | $3.900M | $3.860M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $30.16M | $15.80M | $15.80M |
YoY Change | 90.91% | 236.47% | 236.89% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $7.880K | $22.64K | $20.00K |
YoY Change | -60.6% | -9.5% | -33.33% |
Goodwill | $8.866M | ||
YoY Change | 0.0% | ||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $186.0K | $247.1K | $250.0K |
YoY Change | -25.6% | -19.94% | -19.35% |
Total Long-Term Assets | $10.67M | $9.136M | $9.130M |
YoY Change | 16.87% | -0.7% | -0.76% |
TOTAL ASSETS | |||
Total Short-Term Assets | $30.16M | $15.80M | $15.80M |
Total Long-Term Assets | $10.67M | $9.136M | $9.130M |
Total Assets | $40.83M | $24.93M | $24.93M |
YoY Change | 63.79% | 79.44% | 79.48% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $1.543M | $1.854M | $1.850M |
YoY Change | -16.59% | 3.51% | 3.35% |
Accrued Expenses | $553.3K | $400.0K | $380.0K |
YoY Change | 45.6% | 100.0% | 137.5% |
Deferred Revenue | $0.00 | ||
YoY Change | -100.0% | ||
Short-Term Debt | $0.00 | $500.0K | $480.0K |
YoY Change | -100.0% | 0.0% | -4.0% |
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $2.111M | $2.800M | $2.770M |
YoY Change | -23.79% | -15.15% | -16.31% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | |||
YoY Change | |||
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $2.111M | $2.800M | $2.770M |
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
Total Liabilities | $2.111M | $2.773M | $2.770M |
YoY Change | -23.79% | -16.31% | -16.31% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$19.43M | ||
YoY Change | 60.88% | ||
Common Stock | $2.381K | ||
YoY Change | 427.94% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $38.72M | $22.16M | $22.16M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $40.83M | $24.93M | $24.93M |
YoY Change | 63.79% | 79.44% | 79.48% |
Cashflow Statement
Concept | 2021 | 2020 Q4 | 2020 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$12.77M | -$1.770M | -$7.352M |
YoY Change | 73.66% | -5.85% | 6.0% |
Depreciation, Depletion And Amortization | $19.18K | $10.00K | $18.06K |
YoY Change | 6.23% | 0.0% | -85.83% |
Cash From Operating Activities | -$10.20M | -$1.370M | -$10.31M |
YoY Change | -1.08% | -48.11% | -10.96% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | $0.00 | $2.600K |
YoY Change | -100.0% | ||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $0.00 | $0.00 | |
YoY Change | -100.0% | ||
Cash From Investing Activities | $0.00 | $0.00 | -$2.600K |
YoY Change | -100.0% | -100.05% | |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | $0.00 | ||
YoY Change | -100.0% | ||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | $28.30M | 2.930M | $17.69M |
YoY Change | 59.92% | 23.11% | 394.33% |
NET CHANGE | |||
Cash From Operating Activities | -$10.20M | -1.370M | -$10.31M |
Cash From Investing Activities | $0.00 | 0.000 | -$2.600K |
Cash From Financing Activities | $28.30M | 2.930M | $17.69M |
Net Change In Cash | $18.10M | 1.560M | $7.380M |
YoY Change | 145.21% | -700.0% | -408.4% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$10.20M | -$1.370M | -$10.31M |
Capital Expenditures | $0.00 | $0.00 | $2.600K |
Free Cash Flow | -$10.20M | -$1.370M | -$10.31M |
YoY Change | -1.1% | -10.93% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2021 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001615219 | |
CY2021 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | |
CY2021 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2021 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2021 | us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#GrantMember | |
CY2020 | us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#GrantMember | |
CY2021 | dei |
Document Type
DocumentType
|
10-K | |
CY2021 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2021 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-12-31 | |
CY2021 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2021 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2021 | dei |
Entity File Number
EntityFileNumber
|
001-36812 | |
CY2021 | dei |
Entity Registrant Name
EntityRegistrantName
|
SALARIUS PHARMACEUTICALS, INC. | |
CY2021 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2021 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
46-5087339 | |
CY2021 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
2450 Holcombe Blvd | |
CY2021 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite X | |
CY2021 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Houston | |
CY2021 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
TX | |
CY2021 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
77021 | |
CY2021 | dei |
City Area Code
CityAreaCode
|
832 | |
CY2021 | dei |
Local Phone Number
LocalPhoneNumber
|
834-6992 | |
CY2021 | dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $ 0.0001 | |
CY2021 | dei |
Trading Symbol
TradingSymbol
|
SLRX | |
CY2021 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2021 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2021 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2021 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2021 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2021 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2021 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2021 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2021 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
CY2021 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2021Q2 | dei |
Entity Public Float
EntityPublicFloat
|
47291038 | USD |
CY2022Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
46697194 | shares |
CY2021 | dei |
Auditor Firm
AuditorFirmId
|
42 | |
CY2021 | dei |
Auditor Name
AuditorName
|
Ernst & Young LLP | |
CY2021 | dei |
Auditor Location
AuditorLocation
|
Houston, Texas | |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29214380 | USD |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
11118614 | USD |
CY2021Q4 | us-gaap |
Grants Receivable Current
GrantsReceivableCurrent
|
0 | USD |
CY2020Q4 | us-gaap |
Grants Receivable Current
GrantsReceivableCurrent
|
3855996 | USD |
CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
949215 | USD |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
822050 | USD |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
30163595 | USD |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
15796660 | USD |
CY2021Q4 | us-gaap |
Grants Receivable Noncurrent
GrantsReceivableNoncurrent
|
1610490 | USD |
CY2020Q4 | us-gaap |
Grants Receivable Noncurrent
GrantsReceivableNoncurrent
|
0 | USD |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
7880 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
22639 | USD |
CY2021Q4 | us-gaap |
Goodwill
Goodwill
|
8865909 | USD |
CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
8865909 | USD |
CY2021Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
185994 | USD |
CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
247113 | USD |
CY2021Q4 | us-gaap |
Assets
Assets
|
40833868 | USD |
CY2020Q4 | us-gaap |
Assets
Assets
|
24932321 | USD |
CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1543096 | USD |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1853756 | USD |
CY2021Q4 | flks |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
553269 | USD |
CY2020Q4 | flks |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
383138 | USD |
CY2021Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
0 | USD |
CY2020Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
477028 | USD |
CY2021Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
14518 | USD |
CY2020Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
59211 | USD |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
2110883 | USD |
CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
2773133 | USD |
CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2021Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
45241808 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23810541 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
45241808 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23808546 | shares |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4524 | USD |
CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2381 | USD |
CY2021Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
70915653 | USD |
CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
41585761 | USD |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-32197192 | USD |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-19428954 | USD |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
38722985 | USD |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
22159188 | USD |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
40833868 | USD |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
24932321 | USD |
CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
1840216 | USD |
CY2020 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
5233301 | USD |
CY2021 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8548520 | USD |
CY2020 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6913853 | USD |
CY2021 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6104627 | USD |
CY2020 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6105793 | USD |
CY2021 | us-gaap |
Operating Expenses
OperatingExpenses
|
14653147 | USD |
CY2020 | us-gaap |
Operating Expenses
OperatingExpenses
|
13019646 | USD |
CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12812931 | USD |
CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7786345 | USD |
CY2021 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-44693 | USD |
CY2020 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-258551 | USD |
CY2021 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
0 | USD |
CY2020 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
175540 | USD |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12768238 | USD |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7352254 | USD |
CY2021 | us-gaap |
Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
|
0 | USD |
CY2020 | us-gaap |
Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
|
396407 | USD |
CY2021 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-12768238 | USD |
CY2020 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7748661 | USD |
CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.31 | |
CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.31 | |
CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.50 | |
CY2020 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.50 | |
CY2021 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.31 | |
CY2020 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.50 | |
CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
41365955 | shares |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
41365955 | shares |
CY2020 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
15578611 | shares |
CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15578611 | shares |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12768238 | USD |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7352254 | USD |
CY2021 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
19183 | USD |
CY2020 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
18058 | USD |
CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
559044 | USD |
CY2020 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
319391 | USD |
CY2021 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-44693 | USD |
CY2020 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-258551 | USD |
CY2021 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
-2245506 | USD |
CY2020 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
3855996 | USD |
CY2021 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
70470 | USD |
CY2020 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1140117 | USD |
CY2021 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-310660 | USD |
CY2020 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2782 | USD |
CY2021 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
170131 | USD |
CY2020 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
222355 | USD |
CY2021 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
0 | USD |
CY2020 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-541701 | USD |
CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-10200197 | USD |
CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-10311363 | USD |
CY2021 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | USD |
CY2020 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2600 | USD |
CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | USD |
CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-2600 | USD |
CY2021 | us-gaap |
Proceeds From Other Equity
ProceedsFromOtherEquity
|
27287638 | USD |
CY2020 | us-gaap |
Proceeds From Other Equity
ProceedsFromOtherEquity
|
14798944 | USD |
CY2021 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1485353 | USD |
CY2020 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
3869168 | USD |
CY2021 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
477028 | USD |
CY2020 | flks |
Prepaid Expense Financed By Note Payable
PrepaidExpenseFinancedByNotePayable
|
949131 | USD |
CY2020 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
974435 | USD |
CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
28295963 | USD |
CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
17693677 | USD |
CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
18095766 | USD |
CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
7379714 | USD |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
11118614 | USD |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
3738900 | USD |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
29214380 | USD |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
11118614 | USD |
CY2021 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1468 | USD |
CY2020 | us-gaap |
Interest Paid Net
InterestPaidNet
|
8663 | USD |
CY2021 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | USD |
CY2020 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
8657 | USD |
CY2021 | flks |
Stock Issuance Costs Accrued And Amortized
StockIssuanceCostsAccruedAndAmortized
|
0 | USD |
CY2020 | flks |
Stock Issuance Costs Accrued And Amortized
StockIssuanceCostsAccruedAndAmortized
|
56915 | USD |
CY2021 | flks |
Prepaid Expense Financed By Note Payable
PrepaidExpenseFinancedByNotePayable
|
USD | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10580854 | USD |
CY2020 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
14798944 | USD |
CY2020 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
0 | USD |
CY2020 | flks |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
3812253 | USD |
CY2020 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
269393 | USD |
CY2020 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
49998 | USD |
CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
396407 | USD |
CY2020 | us-gaap |
Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
|
396407 | USD |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7352254 | USD |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
22159188 | USD |
CY2021 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
27287638 | USD |
CY2021 | flks |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
1485353 | USD |
CY2021 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
559044 | USD |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12768238 | USD |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
38722985 | USD |
CY2021 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div> | |
CY2021 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
ReclassificationCertain reclassifications of prior period presentations have been made to conform to the current period presentation. | |
CY2021 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
CY2020 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
CY2021 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | USD |
CY2020 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | USD |
CY2021 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (“FDIC”). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div> | |
CY2021 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9531198 | shares |
CY2020 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10796149 | shares |
CY2021Q4 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
1600000 | USD |
CY2020Q4 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
3900000 | USD |
CY2021Q4 | flks |
Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
|
97557 | USD |
CY2020Q4 | flks |
Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
|
0 | USD |
CY2021Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
678672 | USD |
CY2020Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
684268 | USD |
CY2021Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
172986 | USD |
CY2020Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
137782 | USD |
CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
949215 | USD |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
822050 | USD |
CY2020Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
500000 | USD |
CY2016Q2 | flks |
Revenue From Grants Maximum Award
RevenueFromGrantsMaximumAward
|
18700000 | USD |
CY2016Q3 | flks |
Revenue From Grants Maximum Award
RevenueFromGrantsMaximumAward
|
16100000 | USD |
CY2016Q2 | flks |
Revenue From Grants Award Term
RevenueFromGrantsAwardTerm
|
P3Y | |
CY2021Q4 | flks |
Revenue From Grants Revenue Sharing Payments Continued Payments Percent Of Net Sales
RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales
|
0.01 | |
CY2021Q4 | us-gaap |
Grants Receivable
GrantsReceivable
|
1600000 | USD |
CY2020Q4 | us-gaap |
Grants Receivable
GrantsReceivable
|
3900000 | USD |
CY2020Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
3964065 | shares |
CY2020Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
3964065 | shares |
CY2020Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
3964065 | shares |
CY2020Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.182 | |
CY2020Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
3964065 | shares |
CY2020Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
3783522 | shares |
CY2020Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
6200000 | USD |
CY2021 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1500000 | USD |
CY2020 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
3900000 | USD |
CY2019Q3 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
|
1 | shares |
CY2019Q3 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
142711 | shares |
CY2021Q3 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P5Y | |
CY2019Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
15.17 | |
CY2019Q3 | flks |
Class Of Warrant Or Right Threshold Consecutive Trading Days
ClassOfWarrantOrRightThresholdConsecutiveTradingDays
|
10 | day |
CY2021Q4 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P3Y21D | |
CY2020Q4 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P4Y21D | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
79000 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1468118 | shares |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
92191 | USD |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
1196469 | USD |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
166233 | shares |
CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
34.42 | |
CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y6M10D | |
CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | USD |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1468118 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.93 | |
CY2020 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
36613 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
0 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
33766 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0 | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1563972 | shares |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.44 | |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P4Y10M13D | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
175770 | USD |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
73975 | shares |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
35.89 | |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y4M28D | |
CY2020Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
0 | USD |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
79000 | shares |
CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.02 | |
CY2021 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
||
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
45000 | shares |
CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
||
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
0 | shares |
CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
||
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1597972 | shares |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.75 | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y6M | |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | USD |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
683346 | shares |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
4.85 | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P8Y2M15D | |
CY2021Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
0 | USD |
CY2021Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
900000 | USD |
CY2020Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
1300000 | USD |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1468118 | shares |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
79000 | shares |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.2100 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.2100 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
-0.0069 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
0.0063 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.2613 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.2565 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.0040 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
-0.0582 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
-0.0442 | |
CY2021 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | |
CY2020 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
3002819 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
1725015 | USD |
CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
|
121152 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
|
87432 | USD |
CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
50650 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
28048 | USD |
CY2021Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
1931959 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
673186 | USD |
CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
1068451 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
325329 | USD |
CY2021Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
6175031 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
2839010 | USD |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
6175031 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
2839010 | USD |
CY2021Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |